Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older (additional age rules may apply depending on local regulations)
- People who have been diagnosed with a stomach, gastroesophageal junction (GEJ), or esophageal cancer (a specific type called adenocarcinoma) that cannot be surgically removed, has spread locally, or has spread to other parts of the body
- Depending on which part of the trial is involved, the cancer must have tested either "HER2-positive" or "HER2-low" — these are results from a laboratory test done on tumour tissue that measures a specific protein on cancer cells (confirm with trial site which category applies)
- For one part of the trial (Part 1), the cancer must have grown or spread after at least one previous treatment that included a medicine called trastuzumab
- For other parts of the trial (Parts 2–5), the cancer must not have been previously treated for unresectable or metastatic disease
- The cancer must be measurable on scans using a standard measurement system called RECIST 1.1
- Blood tests and other assessments must show that the heart, kidneys, liver, and bone marrow are functioning at an adequate level as defined by the trial protocol
- People who are able to have children must agree to use a highly effective form of contraception, or avoid intercourse, during the trial and after it ends
Who may not be able to join:
- People with a history of a primary immune system disorder, known HIV (in Parts 1–4), or past or active hepatitis B or C infection (in Parts 1–4); or people with active, uncontrolled HIV, hepatitis B, or hepatitis C (in Part 5)
- People with another serious illness that is not well controlled
- People who have a history of lung inflammation not caused by infection (called pneumonitis or interstitial lung disease), currently have this condition, or where this condition cannot be ruled out by scans at the start of the trial
- People with other serious, clinically significant lung conditions
- People with an active infection that requires antibiotic, antiviral, or antifungal treatment given directly into a vein (intravenously)
- People who have a build-up of fluid around the lungs, in the abdomen, or around the heart that requires draining or other procedures to manage it
- People with spinal cord compression or active cancer that has spread to the brain or central nervous system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0; Part 1: Ocurrence of dose-limiting toxicities (DLTs); Part 1: Changes from baseline in laboratory parameters; Part 1: Changes from baseline in vital signs; Part 1: Changes from baseline in electrocardiogram (ECG) results; Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.